Ilika Stock Earnings Reports

Ilika is a UK-based developer of solid-state batteries with two product lines: Stereax (miniature cells for implantable medical devices and sensors) and Goliath (large-format cells for EVs and cordless appliances). The company uses an asset-light, IP/licensing-led commercial model (license fees, royalties, NRE/engineering fees, and wafer/assembly revenue) and partners with manufacturing specialists rather than building gigafactories. Key near-term commercial milestones: Cirtec Medical equipment commissioning for Stereax with engineering lots underway and wafer/batch production expected to start in the second half of 2025, targeting customer delivery of the M300 minimum viable product toward the end of 2025; Goliath has validated scale-up at UKBIC, shipped P1 prototypes to customers, is testing 10 Ah P1.5 prototypes (to be released in H2) and plans 50 Ah P2 prototypes later in the year. Recent funding and risk profile: Ilika secured an additional GBP 1.25m grant for Goliath A-sample production and completed an equity raise that increased cash to just over GBP 11m, supporting commercialization and prototype development. Financials reflected lower FY revenue (GBP 1.1m vs. GBP 2.1m prior year) due to timing of grant-funded projects; EBITDA loss widened mainly because of reduced grant income rather than higher operating costs. Main investor considerations: demonstrated industrial validation (Cirtec, UKBIC), clear revenue layering plan (grants, NRE, wafer revenue, royalties, additional licenses), roadmap and prototypes in market for customer validation, but commercialization and volume ramp remain multi-year activities with execution and adoption risks.